Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Robert R. Landman"'
Autor:
Greg M. Arndt, Marc R. Wilkins, Mark J. Raftery, Kathryn Evans, Julia W Bӧhm, Anna Mariana, Tim Failes, Ling Zhong, Michelle Haber, Ignatius Pang, Chelsea Mayoh, Richard B. Lock, Connor D. Jones, Glenn M. Marshall, Murray D. Norris, Stephen W. Erickson, Robert R. Landman, Keith C.S. Sia, Robert Collins
Publikováno v:
Leukemia. 35:3101-3112
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk ALL subtype with high rates of relapse and poor patient outcome. Activating mutations affecting components of the JAK-STAT signaling pathway occur in the majority
Autor:
Naresh Punwani, Evan Cimino, Swamy Yeleswaram, Noam Epstein, Phillip Wang, Robert R. Landman, Xuejun Chen, Brad Yuska, Kevin He, April M. Barbour
Publikováno v:
The Journal of Clinical Pharmacology. 59:1641-1647
Itacitinib is a potent, selective JAK-1 inhibitor currently in phase 3 development for the treatment of acute and chronic graft-versus-host disease (GVHD) in combination with corticosteroids. Itacitinib is primarily eliminated via metabolism by cytoc
Autor:
Luis Féliz, Swamy Yeleswaram, Ekaterine Asatiani, Tao Ji, Christine F. Lihou, Xuejun Chen, Robert R. Landman, Heather Overholt
Publikováno v:
Molecular Cancer Therapeutics. 18:C071-C071
Pemigatinib is a potent inhibitor of fibroblast growth factor receptors (FGFR) 1, 2, and 3 with selectivity against other kinases and is currently being studied in solid tumors expressing FGFR translocations and/or mutations. A first-in-man phase 1 s
Autor:
Yvonne Lo, William V. Williams, Peggy Scherle, Xuejun Chen, Swamy Yeleswaram, Thomas Emm, Naresh Punwani, Robert R. Landman, Jack G. Shi, Ryan F. McGee
Publikováno v:
Clinical Pharmacology in Drug Development. 3:34-42
Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&2 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single-dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%,
Autor:
Swamy Yeleswaram, Naresh Punwani, Ryan F. McGee, Edward G. McKeever, Robert R. Landman, Thomas Emm, Xuejun Chen, Yvonne Lo, William V. Williams, Peggy Scherle, Jack G. Shi
Publikováno v:
The Journal of Clinical Pharmacology. 52:809-818
Ruxolitinib, a selective Janus kinase (JAK) 1&2 inhibitor in development for the treatment of myeloproliferative neoplasms, is primarily metabolized by CYP3A4. The effects of inhibition or induction of CYP3A4 on single oral dose ruxolitinib pharmacok
Autor:
Xuejun, Chen, Jack G, Shi, Thomas, Emm, Peggy A, Scherle, Ryan F, McGee, Yvonne, Lo, Robert R, Landman, Naresh G, Punwani, William V, Williams, Swamy, Yeleswaram
Publikováno v:
Clinical pharmacology in drug development. 3(1)
Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK12 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single-dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%,
Autor:
Ryan F. McGee, Naresh Punwani, Xuejun Chen, Swamy Yeleswaram, Jack G. Shi, Yvonne Lo, William V. Williams, Peggy Scherle, Robert R. Landman, Thomas Emm
Publikováno v:
Journal of clinical pharmacology. 51(12)
INCB018424 phosphate, a potent inhibitor of JAK enzymes with selectivity for JAK1&2, is in development for the treatment of myelofibrosis (MF). The oral dose pharmacokinetics, pharmacodynamics, safety, and tolerability of INCB018424 were evaluated in
Autor:
Bӧhm JW; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Sia KCS; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Jones C; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Evans K; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Mariana A; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Pang I; School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, NSW, Australia., Failes T; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Zhong L; Bioanalytical Mass Spectrometry Facility, UNSW Sydney, Sydney, NSW, Australia., Mayoh C; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Landman R; Incyte Corporation, Wilmington, DE, USA., Collins R; Incyte Corporation, Wilmington, DE, USA., Erickson SW; RTI International, Research Triangle Park, NC, USA., Arndt G; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Raftery MJ; Bioanalytical Mass Spectrometry Facility, UNSW Sydney, Sydney, NSW, Australia., Wilkins MR; School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, NSW, Australia., Norris MD; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Haber M; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia., Marshall GM; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia.; Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia., Lock RB; Children's Cancer Institute, School of Women's and Children's Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia. rlock@ccia.unsw.edu.au.
Publikováno v:
Leukemia [Leukemia] 2021 Nov; Vol. 35 (11), pp. 3101-3112. Date of Electronic Publication: 2021 Apr 24.
Autor:
Gong X; Incyte Research Institute, Wilmington, Delaware, USA., Darpo B; eRT/iCardiac Technologies, Rochester, New York, USA., Xue H; eRT/iCardiac Technologies, Rochester, New York, USA., Punwani N; Incyte Research Institute, Wilmington, Delaware, USA., He K; Incyte Corporation, Wilmington, Delaware, USA., Barbour AM; Incyte Research Institute, Wilmington, Delaware, USA., Epstein N; Incyte Research Institute, Wilmington, Delaware, USA., Landman R; Incyte Research Institute, Wilmington, Delaware, USA., Chen X; Incyte Research Institute, Wilmington, Delaware, USA., Yeleswaram S; Incyte Research Institute, Wilmington, Delaware, USA.
Publikováno v:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 Aug; Vol. 9 (6), pp. 677-688. Date of Electronic Publication: 2019 Dec 10.
Autor:
Barbour AM; Incyte Corporation, Wilmington, DE, USA., Punwani N; Incyte Corporation, Wilmington, DE, USA., Epstein N; Incyte Corporation, Wilmington, DE, USA., Landman R; Incyte Corporation, Wilmington, DE, USA., Cimino E; Incyte Corporation, Wilmington, DE, USA., Yuska B; Incyte Corporation, Wilmington, DE, USA., Wang P; Incyte Corporation, Wilmington, DE, USA., He K; Incyte Corporation, Wilmington, DE, USA., Chen X; Incyte Corporation, Wilmington, DE, USA., Yeleswaram S; Incyte Corporation, Wilmington, DE, USA.
Publikováno v:
Journal of clinical pharmacology [J Clin Pharmacol] 2019 Dec; Vol. 59 (12), pp. 1641-1647. Date of Electronic Publication: 2019 Jul 08.